Convenient fixed dosing —
no weight-based adjustments |
|
 |
No need to weigh patient |
|
|
|
No estimating or rounding to a dosing tier |
|
|
|
No dosing calculations, which may eliminate
potential for error |
|
 |
|
|
|
Unique double-bolus administration |
|
|
|
Two 10-unit IV bolus injections are required for a complete treatment |
|
|
— Two minutes per bolus |
|
|
— Administered 30 minutes apart |
|
|
Easy administration with 2 available kits |
|
Retavase Kit |
|
Includes all materials needed for reconstitution
and administration |
|
— |
2 10.4-unit vials of Retavase |
|
— |
2 10-mL vials of sterile water
for injection, USP |
|
— |
2 10-mL sterile syringes |
|
— |
2 sterile dispensing pins |
|
— |
4 sterile injection needles |
|
— |
2 alcohol swabs |
|
— |
1 package insert |
|
|
|
|
Retavase Half-Kit |
|
Contains a portion of needed materials |
|
— |
1 10.4-unit vial of Retavase |
|
— |
1 10-mL vial of sterile water
for injection, USP |
|
— |
1 sterile dispensing pin |
|
— |
1 package insert |
|
|
|
|
Important Safety Information |
|
Because thrombolytic therapy increases the risk of bleeding, including internal bleeding (such as intracranial, retroperitoneal, gastrointestinal, genitourinary, or respiratory), Retavase should be used only in those patients for whom its use is indicated in the prescribing information
(see "Indications" in the prescribing information). In addition, thrombolytic therapy increases the absolute risk of stroke, including hemorrhagic stroke, in patients of advanced age. Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents. Coronary thrombolysis may result in arrhythmias associated with reperfusion (see "Warnings" in the prescribing information). |
|
|
